




Alopecia

<div>Alopecia classified into:</div> <ul style="list-style-type: none">• Non-cicatricial Alopecia : No clinical sign of tissue inflammation, scarring, or atrophy of skin .• Cicatricial alopecia : Evidence of tissue destruction such as inflammation, atrophy, and scarring is apparent.	
<div>Classification of acquired alopecia</div> <div>Can occur globally or focally : (Causes of hair loss)</div>	
Diffuse (global) hair loss	
Non-scarring	
<div>1- Failure of follicle production</div> <div>2- Hair shaft abnormality</div> <div>3- Abnormality of cycling (shedding)</div> <div><ul style="list-style-type: none">• Telogen effluvium• Anagen effluvium• Loose anagen syndrome• Alopecia areata</div>	
Focal (patchy, localized) hair loss	
Non-scarring	Scarring (cicatricial) alopecia
<div>3- Production decline :</div> <div><ul style="list-style-type: none">• Triangular alopecia• Pattern hair loss (androgenetic alopecia)</div> <div>4- Hair breakage :</div> <div><ul style="list-style-type: none">• Trichotillomania• Traction alopecia• Infection (tinea capitis)• Primary or acquired hair shaft abnormality</div> <div>5- Unruly hair.</div> <div>6- Abnormality of cycling :</div> <div><ul style="list-style-type: none">• Alopecia areata• Secondary syphilis (alopecia areolaris) (“moth-eaten” appearance in beard or scalp).</div>	<div>1- Lymphocytic :</div> <div><ul style="list-style-type: none">• Chronicl cutaneous (discoïd) lupus erythematosus• Lichen planopilaris (LPP)• Classic pseudopelade of Brocq• Central centrifugal cicatricial alopecia• Alopecia mucinosa• Kertosis follicularis spinulosa decalvans</div> <div>2- Neutrophilic :</div> <div><ul style="list-style-type: none">• Folliculitis decalvans• Dissecting folliculitis (cellulitis)</div> <div>3- Mixed :</div> <div><ul style="list-style-type: none">• Folliculitis keloidalis• Folliculitis necrotica• Erosive pustular dermatosis</div> <div>4- Non-specific :</div> <div><ul style="list-style-type: none">• Trauma.• Chemical or physical burn.• Surgical wound• Neoplasm (Basal cell carcinoma ,Squamous cell carcinoma)</div>
Scarring (cicatricial) alopecia	
<div>• Primary cicatricial alopecia (PCA) results from damage or destruction of the hair follicles stem cells by:</div> <div><ul style="list-style-type: none">- Inflammatory (usually noninfectious) processes- Infection: e.g., “kerion” tinea capitis, necrotizing herpes zoster- Other pathologic processes: surgical scar, primary or metastatic neoplasm.</div> <div>• Manifestations: Effacement of follicular orifices in a patchy or focal distribution, usually in scalp or beard.</div> <div>• The end result is effacement of follicular orifices & replacement of the follicular structure by fibrous tissue.</div> <div>• Scarring is irreversible. Therapies are ineffective.</div>	
TELOGEN EFFLUVIUM	ANAGEN EFFLUVIUM
<div>• Telogen effluvium (TE) is the transient increased shedding of normal club (telogen) hairs from resting scalp follicles.</div> <div>• Secondary to accelerated shift of anagen (growth phase) into catagen and telogen (resting phase)</div> <div>• Results in increased daily hair loss and, if severe, diffuse thinning of scalp hair.</div> <div>Etiology:</div> <div>A reaction pattern to a variety of physical or mental stressors :</div> <div>• Endocrine :</div> <div><div>1- Hypo- or hyperthyroidism ;</div><div>2- postpartum ;</div><div>3- discontinuation or changing type of estrogen containing drugs</div></div> <div>• Nutritional:</div> <div><div>1- Deficiency: biotin, zinc, iron, essential fatty acid</div><div>2- Rapid weight loss,</div><div>3- caloric or protein deprivation,</div><div>4- excessive vitamin A ingestion</div></div> <div>• Physical stress :</div> <div><div>1- Febrile illnesses,</div><div>2- catabolic illnesses (e.g., malignancy, chronic infection),</div><div>3- major surgery,</div><div>4- major trauma,</div><div>5- acute or chronic psychological stress</div></div> <div>• Psychological stress :</div> <div><div>1- Anxiety,</div><div>2- depression,</div><div>3- bipolar disorder</div></div> <div>• Intoxication : Thallium, mercury, arsenic</div> <div>• Drugs :</div> <div><div>1- Antimitotic agents (dose dependent): cancer chemotherapy, benzimidazoles.</div><div>2- Antihypertensives: captopril</div><div>3- Anticoagulants</div><div>4- CNS drugs: lithium, valproic acid</div><div>5- Cholesterol-lowering drugs</div><div>6- Colchicine</div><div>7- Cytostatic drugs</div><div>8- Interferon</div><div>9- Penicillamine</div><div>10- Retinoids: vitamin A excess, retinoids (isotretinoin, acitretin, indinavir)</div><div>11- Selective serotonin reuptake inhibitors</div><div>12- Inflammatory scalp disease: Seborrheic dermatitis, erythroderma</div></div> <div>• Idiopathic :</div> <div>No obvious cause is apparent in a significant number of cases.</div>	<div>• Etiology: See below</div> <div>• Onset is usually rapid & extensive.</div> <div>• Pathogenesis: Occurs after any insult to hair follicle that impairs its mitotic/metabolic activity. Rapid growth arrest or damage to anagen hairs that skip catagen and telogen phases and are shed.</div> <div>• More common and severe with combination chemotherapy than with the use of a single drug. Severity is generally dose dependent.</div> <div>• Manifestations:</div> <div><div>Scalp hair : loss is diffuse, extensive; also: eyebrows/lashes, beard, etc.</div><div>Nails: show transverse banding or ridging.</div></div> <div>• Regrowth is usually rapid after discontinuation of Chemotherapy</div> <div>Etiology:</div> <div>Anagen cycle disrupted causing varying degrees of hair follicle dystrophy :</div> <div>• Radiation therapy to head .</div> <div>• Alkylating agents:</div> <div>busulfan, carboplatin, carmustine, BCNU, chlorambucil, cisplatin, dacarbazine, estramustine, fotemustine, ifosamide, lomustine, mechlorethamine, nitrogen mustard, melphalan, oxaliplatin, procarbazine, streptozocin, temozolomide, thioteпа.</div> <div>• Intoxications:</div> <div>mercury, boric acid, thallium, colchicine.</div> <div>• Severe protein malnutrition.</div>

Alopecia areata	
<ul style="list-style-type: none">• A localized loss of hair in round or oval areas with no apparent inflammation of the skin. Most common on scalp.• Nonscarring; hair follicle intact; hair can regrow.• Clinical findings: Hair loss ranging from solitary patch to complete loss of all terminal hair.• Prognosis: good for limited involvement. Poor for extensive hair loss.• Management: intralesional triamcinolone effective for limited number of lesions.	
PATHOGENESIS	DIFFERENTIAL DIAGNOSIS
<div>• Chronic organ-specific autoimmune disease, mediated by autoreactive T cells affecting hair follicles and nails.</div> <div>• Associated autoimmune disorders: Autoimmune thyroid disease in adults.</div> <div>• Follicular damage occurs in anagen followed by → rapid transformation to catagen and to → telogen; then to → dystrophic anagen status.</div> <div>While the disease is active, follicles unable to progress beyond early anagen and do not develop normal hair.</div>	<div>Nonscarring Alopecia :</div> <div><ul style="list-style-type: none">• White-patch tinea capitis,• Trichotillomania,• Early scarring alopecia,• Pattern hair loss,• Secondary syphilis (alopecia areolaris) (“moth-eaten” appearance)</div>
CLINICAL MANIFESTATIONS	LABORATORY EXAMINATIONS
<div>Age: Any age , but peak between 20 – 50 years</div> <div>Sex : affect both sexes.</div> <div>Duration of Hair Loss</div> <div>Gradual over weeks to months.</div> <div>Skin Symptoms</div> <div>Disfiguring bald patch.</div> <div>Associated Findings</div> <div><ul style="list-style-type: none">• Autoimmune thyroiditis.• Down syndrome.• Autoimmune polyendocrinopathy-candidiasis–ectodermal dysplasia syndrome.</div>	<div>• Serology :</div> <div><div>1- ANA (to rule out SLE);</div><div>2- rapid plasma reagin (RPR) test (to rule out secondary syphilis).</div></div> <div>• KOH Preparation: Rule out tinea capitis.</div> <div>• Dermatopathology :</div> <div>Acute lesions show :</div> <div><div>- peribulbar, perivascular, and outer root sheath mononuclear cell infiltrate of T cells and macrophages;</div><div>- follicular dystrophy with abnormal pigmentation and matrix degeneration.</div></div>
Skin Findings	MANAGEMENT
<div>- Usually none.</div> <div>- Possibly minimal erythema in area of hair loss.</div>	<div><i>No curative treatment is currently available. Treatment for AA is unsatisfactory.</i></div> <div>Treatment directed at inflammatory infiltrate and growth inhibitor factors produced by inflammation.</div> <div>1- General measures :</div> <div><ul style="list-style-type: none">• Psychological support (very important).• Persons with extensive scalp involvement such as AAT may prefer to wear a wig or hairpiece.• Makeup applied to eyebrows is helpful. Eyebrows can be tattooed.</div> <div>2- Glucocorticoids</div> <div>• Glucocorticoids Topical :</div> <div>Superpotent agents not usually effective.</div> <div>• Intralesional Injection :</div> <div>Few and small lesions of AA can be treated with intralesional triamcinolone acetonide, 3–7 mg/mL, which can be very effective temporarily.</div> <div>• Systemic Glucocorticoids :</div> <div>May induce regrowth, but AA recurs on discontinuation; risks of long-term therapy therefore preclude their use.</div> <div>3- Systemic Cyclosporine</div> <div>Induces regrowth, but AA recurs when drug is discontinued.</div> <div>4- Induction of Allergic Contact Dermatitis -</div> <div>By Dinitrochlorobenzene (DNCP) , but local discomfort due to allergic contact dermatitis and swelling of regional lymph nodes poses a problem.</div> <div>5- Oral PUVA (Photochemotherapy) :</div> <div>Entire body must be exposed, in that the therapy is believed to be a form of systemic immune suppression.</div> <div>• Patchy alopecia :</div> <div><div>○ Intralesional corticosteroids : Up to 2 mL injected/session and repeated at intervals.</div><div>○ Potent topical steroid (1-2×/day).</div><div>○ Topical anthralin (0.1%-2.0% once daily) : Wash off after 10-20 min, steadily increase contact duration, switch to higher dose if no significant irritation.</div><div>○ Minoxidil lotion (5%) twice daily.</div></div> <div>• Extensive or rapidly progressive alopecia.</div> <div><div>○ Contact immunotherapy.</div><div>○ Systemic corticosteroids.</div><div>Benefits are uncertain and must be weighed against risk of systemic corticosteroid therapy.</div><div>○ Wig or hairpiece.</div></div> <div>• Alopecia totalis/universalis</div> <div><div>○ Contact immunotherapy.</div><div>○ Topical/systemic steroids.</div><div>○ Wig or hairpiece.</div></div>
Hair	COURSE
<div>Round patches of hair loss.</div> <div><ul style="list-style-type: none">• Single or multiple. May coalesce.• It's often sharply defined.• Normal-appearing skin with follicular openings present .• “Exclamation mark” hairs (Fig. 32-8) : Diagnostic broken- off stubby hairs (distal ends are broader than proximal ends) seen at margins of hair loss areas.• Scattered, discrete areas of alopecia (Fig. 32-9) or Confluent with total loss of scalp hair (Fig. 32-10), or generalized loss of body hair (including vellus hair).<div><i>Diffuse AA of scalp (noncircumscribed) gives the appearance of thinned hair; can be difficult to differentiate from pattern hair loss of telogen effluvium, hair loss with thyroid disease.</i></div><div><ul style="list-style-type: none">• With regrowth of hair, new hairs are fine, often white or gray.</div></div>	
Sites of Predilection	
<div>- Scalp (most commonly)</div> <div>- Any hair-bearing area : Beard, eyebrows, eyelashes, pubic hair.</div> <div><ul style="list-style-type: none">• Alopecia areata (AA): Solitary or multiple areas of hair loss.• AA totalis (AAT): Total loss of terminal scalp hair.• AA universalis (AAU): Total loss of all terminal body & scalp hair.• Ophiasis: Bandlike pattern of hair loss over periphery of scalp .</div>	
Nails	
<div><ul style="list-style-type: none">• Fine pitting (“hammered brass”) of dorsal nail plate.• mottled lunula,• trachyonychia (rough nails),• onychomadesis (separation of nail from matrix).</div>	
	<div>FIGURE 32-8</div> <div>Solitary lesion</div> <div>The short, broken-off hair shafts (so-called exclamation point hair) appear as very short stubs emerging from the</div>
	<div>FIGURE 32-9</div> <div>multiple, extensive lesions</div> <div>Multiple, confluent, involved sites on the scalp with “exclamation point hairs.”</div>
	<div>FIGURE 32-10</div> <div>AA totalis</div>

Approach to a jaundiced patient

THE NORMAL ENTEROHEPATIC CIRCULATION


- The **haem** component of spent red cells is normally broken down to bilirubin (mainly in the spleen and bone marrow), bound to albumin and transported to the liver. *This relatively stable protein-pigment complex is insoluble in water and is not excreted in the urine.*
- In the liver, the complex is split and the bilirubin conjugated with glucuronic acid which makes it water-soluble, before it is excreted into the bile canaliculi. *The normal concentration of both conjugated and unconjugated bilirubin in the blood is very low.*
- Bacterial action in the bowel converts conjugated bilirubin into colourless **urobilinogen** & pigmented **urobilin** which gives the brown colour to normal faeces.
- Some urobilinogen is reabsorbed, passing to the liver in the portal blood, and is then re-excreted in the bile. The entire process is called an **enterohepatic circulation**. A small amount of urobilinogen escapes into the systemic circulation and is excreted in the urine, *colouring it yellow.*

➔ **Bile acids (salts)** are synthesised in the liver from cholesterol-based precursors. These are excreted in bile to the duodenum and facilitate lipid digestion and absorption in the small intestine. About 95% of the bile acids are reabsorbed in the distal ileum and returned to the liver via the portal vein, only to be re-excreted in the bile ➔ Thus both bilirubin and bile acids are involved in enterohepatic circulations.

PATHOPHYSIOLOGY OF OBSTRUCTIVE JAUNDICE

If biliary outflow becomes obstructed :

- Conjugated bilirubin is dammed back in liver from where it enters bloodstream and causes a gradual rise in plasma bilirubin.
- Once the plasma bilirubin level exceeds about 30 µmol/L, jaundice should be clinically detectable. Above 60 µmol/L, jaundice is obvious.
- Urine:** Conjugated bilirubin, being water-soluble, is excreted in the urine, turning it **dark urine**.
- Feces:** Diminished or absent excretion of bile into the bowel ➔ less urobilin ➔ causing **pale faeces**.
Diminished bile acids ➔ **defective fat absorption**
The two combine to give the stool a characteristic '**putty**' colour.
- Skin:** Biliary obstruction also dams back bile acids, which raises their blood concentration leading to ➔ deposition in skin – causing **intense itching**.
➔ A consequence of poor dietary fat absorption is **malabsorption of vitamin K** ➔ leading to decreased hepatic synthesis of clotting factors (prothrombin) .
 - Impairment of blood clotting is not so great as to cause spontaneous haemorrhage or bruising but there is a significant risk of haemorrhage during surgery.
 - Thus the patient's coagulation profile must be checked before any invasive procedure.
 - The coagulopathy is corrected with parenteral vitamin K or, in the case of an urgent procedure, fresh frozen plasma.



Approach to a jaundiced patient

History-taking

➔ Change in colour of urine and stools, i.e. **dark urine & pale stools** .

- Gall stone disease**, Enquiry about :
 - Episodes of pain typical of gallstone disease,
 - Previous episodes of obstructive jaundice which resolved spontaneously,
 - Previous attacks of acute pancreatitis also suggest gallstone disease.
- Iatrogenic:** Previous biliary tract surgery.
- Drug history:** e.g : oral contraceptive pill-potential for intrahepatic cholestasis
- Risk factors for viral hepatitis:** blood product transfusion, intravenous drug abuse, tattoos, shellfish ingestion, sexual exposure.
- Alcohol intake:** if excessive, predisposes to pancreatitis & cirrhosis
- Symptoms suggestive of malignancy:** anorexia, weight loss & non-specific upper GIT disturbance is common in carcinoma of the pancreas
- History of inflammatory bowel disease:** predisposes to **sclerosing cholangitis** (rare).


Examination

General examination:

- Jaundice** : is first detectable in the sclera of the eye.
- Scratch marks** : In some cases of obstructive jaundice, the patient develops generalised itching (pruritus) and scratch marks
- Stigmata of liver disease:** such as : spider naevi and liver 'flap', are only found when jaundice is caused by primary liver disease
- Enlarged left supraclavicular node (Virchow's node) or periumbilical nodule (Sister Mary Joseph's nodule) suggests an : **abdominal malignancy**.
- Jugular venous distention, a sign of right-sided heart failure, suggests : **hepatic congestion** .

Local Abdominal Examination: Abdomen should be examined for :

- Ascites:** Ascites in the presence of jaundice suggests either : 1- cirrhosis or 2- malignancy with peritoneal spread.
- Enlarged liver or spleen :**
 - An enlarged nodular liver may be caused by primary or secondary malignancy.
 - Splenomegaly & hepatomegaly is an important sign of chronic parenchymal liver disease (usually cirrhosis) & indicates portal hypertensor
- Abnormal masses :** Obvious abdominal mass suggests malignancy.
- Palpable gall bladder :**
 - Courvoisier's 'law'** : states that obstructive jaundice in the presence of a palpable gall bladder is not due to stone (and is therefore likely to be caused by tumour) :
 - In gall stone: - Gallstones cause chronic inflammation leading to: fibrosis of the gall bladder, which **prevents its distension**.
 - Intermittent stone obstruction leads to : thickening of the gall bladder wall, which **prevents its distension**.
 - In malignancy:
 - Progressive obstruction occurs over a short period and the gall bladder distends easily.
- Rectal Examination :** Pale stool is characteristic of obstructive jaundice.
➔ The urine should be inspected : - dark yellow or orange from the presence of conjugated bilirubin, and
- froths when shaken due to the detergent effect of bile acids.



Approach to investigation of jaundice , step by step as follows:

Laboratory :

- Urine tests :** Presence of substantial quantities of bilirubin in the urine which is established by: 1- clinic al or 2- bedside dipstick urine tests
- Blood tests :** ➔
 - Enzyme tests :** To differentiate between : a **hepatocellular process** & **cholestatic process**
 - Patients with a hepatocellular process** : have a disproportionate rise in the aminotransferases compared to the ALP.
 - Patients with a cholestatic process:** have a disproportionate rise in the ALP compared to the aminotransferases.
 - The bilirubin can be prominently elevated in both hepatocellular & cholestatic conditions ➔, therefore, is not necessarily in differentiating.*
 - Assessment of liver function :** All jaundiced patients should have additional blood tests, to assess liver function :
 - Albumin level:** - Low albumin level suggests a chronic process such as cirrhosis or cancer.
- Normal albumin level is suggestive of a more acute process such as viral hepatitis or choledocholithiasis
 - Prothrombin time:**
 - An elevated prothrombin time indicates either 1- Vitamin K deficiency ,due to prolonged jaundice & malabsorption of vitamin K or 2- Significant hepatocellular dysfunction.The failure of the prothrombin time to correct with parenteral administration of vitamin K indicates severe hepatocellular injury.

➔ **By liver function tests, Obstructive jaundice is characterised by :**

- Elevated level of plasma bilirubin, predominantly in the conjugated form.
- There is marked elevation of plasma ALP , which is derived from bile canaliculi.
- The transaminases, derived from hepatocytes, are usually only mildly elevated

➔ When pattern of the liver tests suggests a **cholestatic disorder**, the next step is to determine whether it's :

- Intra- hepatic cholestasis or
- Extra- hepatic cholestasis.

➔ Distinguishing intrahepatic from extrahepatic cholestasis may be difficult. History, physical examination, and laboratory tests are often not helpful.

➔ The next appropriate test is an **ultrasound**.

Imaging :

A) Hepatobiliary ultrasonography, shows :

- U/S can detect dilation of the intra- and extrahepatic biliary tree :
Absence of biliary dilatation suggests: **intrahepatic cholestasis** / while Presence of biliary dilatation indicates: **extrahepatic cholestasis**.
- Liver secondaries
- Gall bladder abnormalities including stones.
➔ Although ultrasonography may indicate extrahepatic cholestasis, **it rarely identifies the site or cause of obstruction**.
➔ The distal common bile duct is a particularly difficult area to visualize by ultrasound because of overlying bowel gas.

Appropriate next tests include: CT, & ERCP.

B) CT scanning : CT scanning & MRCP are better than ultrasonography for :

- Assessing the head of the pancreas and
- Assessment distal common bile duct for a- choledocholithiasis , particularly when the ducts are not dilated b- small carcinoma .

C) Endoscopy-diagnostic & therapeutic

- If **ultrasound demonstrates dilated ducts ➔ ERCP** is frequently next investigation (gold standard for identifying & ttt choledocholithiasis).
- If ERCP failed ➔ Percutaneous Transhepatic Cholangiopancreatography (PTC).

D) Liver biopsy :

- If **bile ducts are not dilated** (intrahepatic cholestasis) ➔ 1- **Serologic testing in combination with** 2- **Percutaneous liver biopsy**

E) Laparoscopy, indications :

- In patients unsuitable for percutaneous biopsy, or
- Those who require visualisation of other organs,
 - Laparoscopy may be used to visualise the liver directly and to obtain biopsy specimens from suspicious areas.

Occasionally, a firm diagnosis cannot be made before operation ➔ abdominal exploration and frozen section histology + opportunity for treatment at the same time.

